United States Acute Migraine Drugs Market 2025: Novel Therapies, Key Players & Industry Innovation

DataM Intelligence has published a new research report on "Acute Migraine Drugs Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/acute-migraine-drugs-market?kb

United States: Recent Industry Developments

✅ In September 2025, Amgen received FDA approval for its novel CGRP receptor antagonist for the acute treatment of migraine, expanding therapeutic options for patients with frequent attacks.

✅ In August 2025, Eli Lilly launched an oral ditans formulation for rapid migraine relief, targeting patients who experience nausea with traditional therapies.

✅ In July 2025, Biohaven Pharmaceuticals expanded distribution of its Rimegepant tablets in U.S. specialty pharmacies to improve accessibility for migraine sufferers.

✅ In June 2025, Teva Pharmaceuticals initiated clinical trials for a next-generation acute migraine therapy with improved onset of action and tolerability.

✅ In May 2025, AbbVie partnered with a digital health platform to integrate migraine tracking with personalized medication recommendations, enhancing patient adherence and outcomes.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceutical launched a new orally disintegrating acute migraine therapy for faster relief and improved patient compliance.

✅ In August 2025, Eisai Co., Ltd. expanded clinical studies of its CGRP-targeted migraine drug to evaluate long-term efficacy and safety in Japanese patients.

✅ In July 2025, Otsuka Pharmaceutical collaborated with local hospitals to implement migraine patient education programs alongside novel acute therapies.

✅ In June 2025, Sumitomo Dainippon Pharma conducted post-marketing surveillance for its recently approved acute migraine drug, monitoring real-world effectiveness and adverse events.

✅ In May 2025, Astellas Pharma explored combination therapy approaches for acute migraine management, aiming to optimize treatment for refractory patients.

Key Players:

Teva Pharmaceuticals, F Hoffmann-la Roche Ltd, Johnson & Johnson, Pfizer Inc., AstraZeneca, Amgen Inc., Merck & Co., Novartis AG, Eli Lilly and Company, and Sun Pharma

Key Development:

On March 10, 2023, Pfizer Inc. announced that the U.S. FDA approved ZAVZPRET (zavegepant), the first and only CGRP receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 trial, ZAVZPRET demonstrated statistically significant improvements over placebo for co-primary endpoints of pain freedom and freedom from most bothersome symptoms at two hours post-dose, with pain relief observed as early as 15 minutes in a prespecified secondary endpoint.

On February 12, 2023, Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced the acquisition of U.S. and Canadian rights to ELYXYBTM (celecoxib oral solution) the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

Growth Forecast Projected:

The Global Acute Migraine Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Acute Migraine Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=acute-migraine-drugs-market

Key Segments:

By Type: (Triptans, NSAIDs, Others)

By Route of Administration: (Oral, Injectable, Nasal sprays, Others)

By End -User: (Hospital Pharmacies, Drug Stores)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Acute Migraine Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Acute Migraine Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/acute-migraine-drugs-market?kb

FAQ's

Q1: What is the current size of the Acute Migraine Drugs Market?

A: The Acute Migraine Drugs Market stood at US$ 10.1 billion in 2022 and is set to experience remarkable growth, reaching US$ 18.6 billion by 2030

Q2: How fast is the Acute Migraine Drugs Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 8.1% from 2025 to 2032

Q3: Which regions are dominating the Acute Migraine Drugs Market and which are fastest-growing?

A: North America dominating the Acute Migraine Drugs market.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/acute-migraine-drugs-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.